Section Arrow
PPBT.NASDAQ
- Purple Biotech Ltd
Quotes are at least 15-min delayed:2025/06/12 07:26 EDT
Last
 2.56
-0.1341 (-4.98%)
Day High 
2.655 
Prev. Close
2.6941 
1-M High
2.8 
Volume 
11.79K 
Bid
2.45
Ask
2.65
Day Low
2.54 
Open
2.64 
1-M Low
2.16 
Market Cap 
7.13M 
Currency USD 
P/E 0.01 
%Yield -- 
10-SMA 2.61 
20-SMA 2.47 
50-SMA 2.5 
52-W High 13.95 
52-W Low
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
476.10/-0.62
Enterprise Value
7.13M
Balance Sheet
Book Value Per Share
12.33
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
NCNANuCana plc0.165+0.0215+14.98%-- 
VXRTVaxart0.5041+0.1112+28.30%-- 
KZIAKazia Therapeutics Limited9.54+4.2847+81.53%-- 
KLTOKlotho Neurosciences Inc1.45-0.56-27.86%-- 
CARMCarisma Therapeutics0.6032-0.5068-45.66%-- 
Quotes are at least 15-min delayed:2025/06/12 07:26 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.